Evidence map›Paper›PMID 35898346›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Impact of Pre-Existing Chronic Viral Infection and Reactivation on the Development of Long COVID.

Michael J Peluso, Tyler-Marie Deveau, Sadie E Munter, Dylan Ryder, Amanda Buck, Gabriele Beck-Engeser, Fay Chan, Scott Lu, Sarah A Goldberg, Rebecca Hoh and 22 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 40 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 1 institution in 1 country.

Michael J PelusoDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.
Tyler-Marie DeveauDivision of Experimental Medicine, University of California, San Francisco, CA, USA.
Sadie E MunterDivision of Experimental Medicine, University of California, San Francisco, CA, USA.
Dylan RyderDivision of Experimental Medicine, University of California, San Francisco, CA, USA.
Amanda BuckDivision of Experimental Medicine, University of California, San Francisco, CA, USA.
Gabriele Beck-EngeserDivision of Experimental Medicine, University of California, San Francisco, CA, USA.
Fay ChanDivision of Experimental Medicine, University of California, San Francisco, CA, USA.
Scott LuDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Sarah A GoldbergDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Rebecca HohDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.
Viva TaiDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.
Leonel TorresDivision of Experimental Medicine, University of California, San Francisco, CA, USA.
Nikita S IyerDivision of Experimental Medicine, University of California, San Francisco, CA, USA.
Monika DeswalDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.
Lynn H NgoDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.
Melissa BuitragoDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.
Antonio RodriguezDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.
Jessica Y ChenDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.
Brandon C YeeMonogram Biosciences Inc., South San Francisco, CA, USA.
Ahmed ChennaMonogram Biosciences Inc., South San Francisco, CA, USA.
John W WinslowMonogram Biosciences Inc., South San Francisco, CA, USA.
Christos J PetropoulosMonogram Biosciences Inc., South San Francisco, CA, USA.
Amelia N DeitchmanSchool of Pharmacy, University of California, San Francisco CA, USA.
Joanna HellmuthDepartment of Neurology, University of California, San Francisco, CA, USA.
Matthew A SpinelliDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.
Matthew S DurstenfeldDivision of Cardiology, University of California, San Francisco, CA, USA.
Priscilla Y HsueDivision of Cardiology, University of California, San Francisco, CA, USA.
J Daniel KellyDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Jeffrey N MartinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Steven G DeeksDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.
Peter W HuntDivision of Experimental Medicine, University of California, San Francisco, CA, USA.
Timothy J HenrichDivision of Experimental Medicine, University of California, San Francisco, CA, USA.
University of California, San Francisco · US

Funding

Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
Targeting Non Viral Markers of HIV PersistenceR01AI141003 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HENRICH, TIMOTHY JENSEN · 2018 to 2022
$4.9M
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV InfectionR01HL152957 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER W HUNT, Priscilla Y. Hsue · 2020 to 2026
$3.7M
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinicR01AI158013 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2020 to 2023
$3.1M
UCSF Career Development Program in Cardiopulmonary, Hematologic, and Immunologic Comorbidities of HIV (CHIC)K12HL143961 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSUE, PRISCILLA Y., HUANG, LAURENCE · 2018 to 2022
$1.8M
Persistent Functional Immune Defects in Treated HIV InfectionK24AI145806 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUNT, PETER W · 2020 to 2024
$921k
Evaluation of the Impact of HIV Status on the Immune Response to mRNA COVID-19 VaccinesR21AI167648 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2022 to 2023
$444k
NHLBI NIH HHS K12 HL143961NHLBI NIH HHS R01 HL152957NIAID NIH HHS K24 AI145806NIAID NIH HHS R01 AI141003NIAID NIH HHS R01 AI158013NIAID NIH HHS R21 AI167648NIAID NIH HHS T32 AI060530
6 · The paper itself

Abstract

The presence and reactivation of chronic viral infections such as Epstein-Barr virus (EBV), cytomegalovirus (CMV) and human immunodeficiency virus (HIV) have been proposed as potential contributors to Long COVID (LC), but studies in well-characterized post-acute cohorts of individuals with COVID-19 over a longer time course consistent with current case definitions of LC are limited. In a cohort of 280 adults with prior SARS-CoV-2 infection, we observed that LC symptoms such as fatigue and neurocognitive dysfunction at a median of 4 months following initial diagnosis were independently associated with serological evidence of recent EBV reactivation (early antigen-D [EA-D] IgG positivity) or high nuclear antigen IgG levels, but not with ongoing EBV viremia. Evidence of EBV reactivation (EA-D IgG) was most strongly associated with fatigue (OR 2.12). Underlying HIV infection was also independently associated with neurocognitive LC (OR 2.5). Interestingly, participants who had serologic evidence of prior CMV infection were less likely to develop neurocognitive LC (OR 0.52) and tended to have less severe (>5 symptoms reported) LC (OR 0.44). Overall, these findings suggest differential effects of chronic viral co-infections on the likelihood of developing LC and predicted distinct syndromic patterns. Further assessment during the acute phase of COVID-19 is warranted. SUMMARY: The authors found that Long COVID symptoms in a post-acute cohort were associated with serological evidence of recent EBV reactivation and pre-existing HIV infection when adjusted for participant factors, sample timing, comorbid conditions and prior hospitalization, whereas underlying CMV infection was associated with a decreased risk of Long COVID.

Identifiers

PMID35898346
PMCPMC9327632
OpenAlexW4283261563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.